Gilead increases enrollment target for remdesivir trial in COVID-19 patients [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
Gilead increases enrollment target for remdesivir trial in COVID-19 patients (Reuters) - Gilead Sciences Inc on Friday increased enrollment target by 3,600 for a trial testing its experimental drug, remdesivir, in severe COVID-19 patients, a day after a media report said the drug was showing promise. Shares of the company rose 8% after medical news website STAT detailed rapid recovery in fever and respiratory symptoms in COVID-19 patients at the University of Chicago Medicine hospital. The enrollment estimate in the trial run by Gilead was increased to 6,000 patients from 2,400 previously, according here to clinicaltrials.gov, a register of clinical trials. Brokerage Piper Sandler said rationale for the increase was to widen access to remdesivir and to gather additional data on the drug, noting that there were no additional changes to the goals. Gilead did not immediately respond to Reuters’ request for comment on increased enrolment. The company has previously said it was shifting fr
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Time To Take Profits On Gilead Sciences (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Argus from $135.00 to $165.00. They now have a "buy" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $155.00 price target on the stock.MarketBeat
- Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Mizuho from $140.00 to $170.00. They now have an "outperform" rating on the stock.MarketBeat
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- 2/17/26 - Form 144
- GILD's page on the SEC website